13 research outputs found
Observation of gravitational waves from the coalescence of a 2.5−4.5 M⊙ compact object and a neutron star
AGE AND PHYSICAL ACTIVITY DO NOT IMPACT CIRCULATING SOLUBLE CD14 CONCENTRATION IN APPARENTLY HEALTHY ADULTS
BACKGROUND: Soluble CD14 (sCD14) (cluster of differentiation 14) is a co-receptor of bacterial lipopolysaccharide that is released from monocytes upon activation. There is a well-recognized role of sCD14 in inflammation, and aging has been associated with increased inflammation and cardiometabolic health risk factors (e.g., high blood pressure [BP], hyperglycemia). However, there is limited information on the combined influence of aging and physical activity on circulating sCD14. Therefore, the purpose of this study was to examine the influence of aging on plasma sCD14 concentration and the potential influence of physical activity. METHODS: Twenty young (11 females, age 22.7± 2.6, body mass index 26.7 ± 3.3, BP 119/73 ± 7/8 mmHg) and 21 old (11 female, age 58.4 ± 7.4, body mass index 27.8 ± 4.8, BP 125/76 ± 12/8 mmHg) adults participated in the study. Physical activity (PA) was assessed using waist worn ActiGraph GT3X accelerometers for a minimum of 5-days (7.6 ± 1.6 days) to obtain average daily steps, sedentary time, and moderate and vigorous PA (MVPA). We measured brachial BP using a SpyghmoCor XCEL after 10-minutes of supine rest. We assessed plasma concentrations of sCD14 using an enzyme-linked immunosorbent assay kit. Normality was assessed using Shapiro-Wilk. Students’ T Test or Mann Whitney test were used to make age comparisons between young (\u3c35 years) and older (\u3e45 years) adults. Pearson’s correlation and Spearman’s rho, controlled for age, body mass index, and sex, were used to assess relations between MVPA and steps with sCD14. Statistical significance was set as p ≤ 0.05 RESULTS: There was not a difference between young and older adults in circulating sCD14 concentration (young: 2348 ± 441 vs. older: 2487 ± 541 pg/ml, p = 0.501). There was not a difference between young and older adults in MVPA (young: 47 ± 25 vs. older: 48 ± 24 min/day, p = 0.873) or average daily steps (young: 7179 ± 3171 vs. older: 7797 ± 3595 steps/day, p = 0.679). There were not associations between sCD14 and daily MVPA (r = -0.176, p = 0.343) or Steps (rho = -0.278, p = 0.130). CONCLUSION: Our preliminary data indicate that there were no age differences in circulating sCD14 and no associations between habitual physical activity and circulating sCD14
Packaging of Dinoroseobacter shibae DNA into Gene Transfer Agent Particles Is Not Random
BipA: a tyrosine-phosphorylated GTPase that mediates interactions between enteropathogenic Escherichia coli (EPEC) and epithelial cells
Recommended from our members
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.
In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978.
Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90.
Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.
US National Institutes of Health and Operation Warp Spee